BVI acquires ophthalmic viscoelastic device assets from Croma Pharma

BVI acquired the ophthalmic viscoelastic device (OVD) assets from Croma Pharma GmbH of Austria and launched NuVisc PRO in Europe. The companies also entered an R&D collaboration for additional products.

“BVI, the fastest growing diversified company in ophthalmology, today announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Croma.”prnewswire.com

• 1 source
• prnewswire.comBVI Expands Portfolio with New Viscoelastic; Forges strategic partnership with CromaBVIMay 15, 2020

Summarized from public sources; check the original articles before acting on it.